WO2001092548A3 - Vaccine and gene therapy vector and methods of use thereof - Google Patents

Vaccine and gene therapy vector and methods of use thereof Download PDF

Info

Publication number
WO2001092548A3
WO2001092548A3 PCT/US2001/016610 US0116610W WO0192548A3 WO 2001092548 A3 WO2001092548 A3 WO 2001092548A3 US 0116610 W US0116610 W US 0116610W WO 0192548 A3 WO0192548 A3 WO 0192548A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
vaccine
gene therapy
therapy vector
sendai viruses
Prior art date
Application number
PCT/US2001/016610
Other languages
French (fr)
Other versions
WO2001092548A2 (en
Inventor
Allen Portner
Toru Takimoto
Original Assignee
St Jude Childrens Res Hospital
Allen Portner
Toru Takimoto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by St Jude Childrens Res Hospital, Allen Portner, Toru Takimoto filed Critical St Jude Childrens Res Hospital
Priority to AU2001264824A priority Critical patent/AU2001264824A1/en
Publication of WO2001092548A2 publication Critical patent/WO2001092548A2/en
Publication of WO2001092548A3 publication Critical patent/WO2001092548A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18841—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18843—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Abstract

A method of generating infectious Sendai viruses that comprise a foreign gene is exemplified. Recombinant Sendai viruses that encode antigens obtained from pathogenic paramyxoviruses are disclosed. Methods of using these recombinant Sendai viruses in vaccines are also provided.
PCT/US2001/016610 2000-06-01 2001-05-22 Vaccine and gene therapy vector and methods of use thereof WO2001092548A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001264824A AU2001264824A1 (en) 2000-06-01 2001-05-22 Vaccine and gene therapy vector and methods of use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20870100P 2000-06-01 2000-06-01
US60/208,701 2000-06-01

Publications (2)

Publication Number Publication Date
WO2001092548A2 WO2001092548A2 (en) 2001-12-06
WO2001092548A3 true WO2001092548A3 (en) 2003-03-27

Family

ID=22775651

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/016610 WO2001092548A2 (en) 2000-06-01 2001-05-22 Vaccine and gene therapy vector and methods of use thereof

Country Status (2)

Country Link
AU (1) AU2001264824A1 (en)
WO (1) WO2001092548A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1629004T3 (en) 2003-06-05 2009-02-27 Wyeth Corp Immunogenic compositions comprising venezuelan equine encephalitis virus replicon vectors and paramyxovirus protein antigens
SG190562A1 (en) * 2008-04-18 2013-06-28 Vaxinnate Corp Deletion mutants of flagellin and methods of use
PT2702159T (en) 2011-04-28 2018-10-30 St Jude Childrens Res Hospital Modified sendai virus vaccine and imaging vector
EP2813574B1 (en) * 2013-06-10 2019-02-20 RSV Genius GmbH Semi-live respiratory syncytial virus vaccine
KR20200096904A (en) * 2017-09-15 2020-08-14 오하이오 스테이트 이노베이션 파운데이션 Vaccines for the prevention of respiratory syncytial virus (RSV) infection and methods of making and using vaccines
WO2022207839A2 (en) * 2021-04-01 2022-10-06 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion piv3 f proteins

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0863202A1 (en) * 1995-11-01 1998-09-09 Dnavec Research Inc. Recombinant sendai virus

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0863202A1 (en) * 1995-11-01 1998-09-09 Dnavec Research Inc. Recombinant sendai virus

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CROWE JAMES E JR: "Current approaches to the development of vaccines against disease caused by respiratory syncytial virus (RSV) and parainfluenza virus (PIV): A meeting report of the WHO Programme for Vaccine Development (Nyon, Switzerland, March 27, 1994).", VACCINE, vol. 13, no. 4, 1995, pages 415 - 421, XP002207924, ISSN: 0264-410X *
DATABASE MEDLINE [online] MURPHY ET AL: "Current approaches to the development of vaccines effective against parainfluenza and respiratory syncytial viruses", XP002207926, Database accession no. NLM2845680 *
GARCIN DOMINIQUE ET AL: "A highly recombinogenic system for the recovery of infectious Sendai paramyxovirus from cDNA: Generation of a novel copy-back nondefective interfering virus.", EMBO (EUROPEAN MOLECULAR BIOLOGY ORGANIZATION) JOURNAL, vol. 14, no. 24, 1995, pages 6087 - 6094, XP002207925, ISSN: 0261-4189 *
HURWITZ J L ET AL: "Intranasal Sendai virus vaccine protects African green monkeys from infection with human parainfluenza virus-type one", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 15, no. 5, 5 April 1997 (1997-04-05), pages 533 - 540, XP004059892, ISSN: 0264-410X *
VIRUS RESEARCH, vol. 11, no. 1, 1988, pages 1 - 15 *

Also Published As

Publication number Publication date
AU2001264824A1 (en) 2001-12-11
WO2001092548A2 (en) 2001-12-06

Similar Documents

Publication Publication Date Title
DK1450856T3 (en) Packaging of Immunostimulatory CpG in Virus-Like Particles, Method and Use
DE69333814D1 (en) GENETIC VACCINE AGAINST IMMUNE WEAKNESS VIRUS
EE200300331A (en) Recombinant MVA virus and its use, isolated eukaryotic cell, method for producing recombinant HIV Nef protein and vaccine
LU91367I2 (en) A complete inactivated influenza virus vaccine prepared from a germ strain produced by using reverse genetics and optionally including an adjuvant
NO20001768L (en) Virus encapsulation vaccine, method of preparation and use thereof
DE69739253D1 (en) LIPOSOMAL GRIP VACCINE AND METHOD
IL150602A (en) Proteosome influenza vaccine, method for preparing such and use thereof
EP1683858A3 (en) Viral preparations, vectors, immunogens, and vaccines
EP1270016A4 (en) Aids virus vaccine with the use of sendai virus vector
DE69535018D1 (en) PAPILLOMA VIRUS VACCINE
AU1013601A (en) Method of inducing and/or enhancing an immune response to tumor antigens
MXPA03000061A (en) Manipulation of negative stranded rna viruses by rearrangement of their genes and uses thereof.
WO2001092548A3 (en) Vaccine and gene therapy vector and methods of use thereof
EP1439856A4 (en) Recombinant rabies vaccine and methods of preparation and use
Karkhanis et al. Mucosal vaccine vectors: replication-competent versus replication-deficient poxviruses
HUT72395A (en) Improved vaccine for immunisation against tbe virus infections as well as method for preparing them
WO2002047720A3 (en) Treatment and prevention of ebv infection and ebv-associated disorders
WO2003077859A3 (en) Method of inducing an enhanced immune response against hiv
HK1012421A1 (en) Vaccine against mumps containing a jeryl-lynn virus strain.
WO2003076598A3 (en) Method of inducing an enhanced immune response against hiv
IL148154A0 (en) Vaccine against intra-cellular pathogens
WO2000040261A3 (en) Vaccination method for efficient induction of cytotoxic t lymphocyte response
RU99113870A (en) ORLOV-D Vaccine Strain of the Red-Virus
Keil Vector vaccines of bovine herpesvirus I
MY157873A (en) Recombinant mva virus, and the use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP